跳至主要内容
临床试验/NCT00154427
NCT00154427终止2 期

A Multi-centre, Randomised, Double-blind, Placebocontrolled, Dose Escalation Trial on Safety and Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in the Treatment of Post-operative Bleeding in Patients Following Cardiac Surgery Requiring Cardiopulmonary Bypass

Novo Nordisk A/S64 个研究点 分布在 12 个国家目标入组 172 人开始时间: 2004年8月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
终止
入组人数
172
试验地点
64
主要终点
Incidence of critical, serious adverse events

研究概览

简要总结

This trial is conducted in Africa, Asia, Europe, South America and the United States of America (USA).

The trial is planned to investigate the safety and efficacy of NovoSeven® in the management of post-operative bleeding in patients following cardiac surgery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Post-operative bleeding according to pre-defined criteria for critical bleeding

排除标准

  • 未提供

结局指标

主要结局

Incidence of critical, serious adverse events

时间窗: Within 30 days

次要结局

  • Surgical drainage volume(For the duration of the trial)
  • Amount of transfusions(For the duration of the trial)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (64)

Loading locations...

相似试验